FOR IMMEDIATE RELEASE
Therapeutic Innovation Australia announces outcomes of Round 1 of the Pipeline Accelerator 2020-21 scheme and the launch of Round 2
Therapeutic Innovation Australia (TIA) is pleased to announce the recipients of the first round of the Pipeline Accelerator 2020-21 scheme, and the launch of Round 2. The Pipeline Accelerator voucher scheme aims to lower the financial bar for Australian translational research community to access the high-quality translational research services offered by TIA Consortium.
Round 1 saw the award of $685,000 to twenty-one projects. The awarded recipients and projects are listed below.
Researchers from academia and industry are invited to apply to the next Round for a voucher to reduce the cost of accessing one or more facilities associated with TIA, including core facilities and High-throughput screening (HTS) centres (see this list of eligible facilities).
Vouchers are provided directly to the capability providers at project commencement, allowing this cost saving to be passed to the applicant. Potential projects are identified via an open call. Applications must seek to access an eligible capability provider and the application must be made with this centre’s involvement and agreement. Projects are assessed by an external panel on the basis of their scientific quality and potential for development of a therapeutic product.
Dr Stuart Newman, CEO of TIA, said: “The TIA Pipeline Accelerator scheme is going from strength to strength and has steadily accumulated a cohort of over 60 supported projects. We are now starting to see the benefits from earlier voucher awards in the form of commercial outcomes and clinical trials.”
The scheme closes at 5pm (AEST) on Friday April 30th, 2021.
Therapeutic Innovation Australia (TIA) is a leading not-for-profit research infrastructure organisation that has received funding under the Australian Department of Education and Training’s National Collaborative Research Infrastructure Strategy (NCRIS) since 2008. TIA manages investment in hard and soft infrastructure to enable external access to key translational research capabilities, thereby enabling and accelerating translation of research discoveries towards clinical testing. To do this, TIA invests NCRIS funds in a consortium of capabilities that provide the translational benefits via state-of-the-art laboratory equipment and highly trained and experienced technical staff.
For more information, please contact: